RxDoctor Payments DataLook up a doctor →

Micaela Perkins, NP

Nurse Practitioner · Oxford, MSNPI 1598130114

Payments from drug & device makers

$31,865in general payments, 2019–2025

Across 910 payments — averaging $35.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$20K
  • AbbVie$3K
  • Johnson & Johnson$1K
  • Novartis$1K
  • Boehringer Ingelheim$921
  • UCB, Inc.$800
  • plus $4K from 17 others

What the payments were for

  • Consulting fees$1,8006%
  • Speaking & faculty fees$11,10035%
  • Travel & lodging$1,7295%
  • Food & beverage$17,01653%
  • Education$2201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,865 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$42,057
Medicare patients
389
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab109$745,395
Enbrel SureclickEtanercept51$361,891
RinvoqUpadacitinib44$275,407
Actemra ActpenTocilizumab38$141,985
Enbrel MiniEtanercept18$129,272
ActemraTocilizumab28$89,479
KevzaraSarilumab20$79,062
Orencia ClickjectAbatacept11$59,718
OtezlaApremilast14$56,678
Hydroxychloroquine Sulfate333$14,233
MethotrexateMethotrexate Sodium236$5,519
Leflunomide94$4,321
Gabapentin168$2,343
Febuxostat26$2,238
Colchicine34$1,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,075$275,40744 claims
SanofiKevzara$123$79,06220 claims
AmgenOtezla$19,992$56,67814 claims
Scilex Pharmaceuticals Inc.Colchicine$67$1,89434 claims
Fresenius Kabi USA, LLCSodium Chloride$333$5227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →